Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael Weller

Showing results (591-600 of 831) with videos related to

Pageof 84
Sort By:
Genome Biology|January 28, 2015
Chromosome 7 gain and DNA hypermethylation at the HOXA10 locus are associated with expression of a stem cell related HOX-signature in glioblastomaSebastian Kurscheid, Pierre Bady, Davide Sciuscio, et al.
Neuro-Oncology|May 25, 2019
Defining EGFR amplification status for clinical trial inclusionPim J French, Marica Eoli, Juan Manuel Sepulveda, et al.
Brain Pathology (Zurich, Switzerland)|August 31, 2025
cIMPACT-NOW update 11: Proposal on adaptation of diagnostic criteria for IDH- and H3-wildtype diffuse high-grade gliomas and for posterior fossa ependymal tumorsPieter Wesseling, David Capper, Guido Reifenberger, et al.
Nature Medicine|April 1, 2008
Ceramide accumulation mediates inflammation, cell death and infection susceptibility in cystic fibrosisVolker Teichgräber, Martina Ulrich, Nicole Endlich, et al.
Neuro-Oncology|February 11, 2026
The prognostic impact of CDKN2A/B hemizygous deletions in meningiomaFranziska M Ippen, Thomas Hielscher, Areeba Patel, et al.
Neuro-Oncology Practice|March 9, 2026
Ethical considerations in randomization for neurosurgical oncology trials: A scoping reviewNathan A Shlobin, Mira C Hasner, Philipp Karschnia, et al.
Neurology|September 27, 2013
Prognostic or predictive value of MGMT promoter methylation in gliomas depends on IDH1 mutationWolfgang Wick, Christoph Meisner, Bettina Hentschel, et al.
Clinical and Translational Radiation Oncology|December 4, 2023
Re-irradiation of recurrent IDH-wildtype glioblastoma in the bevacizumab and immunotherapy era: Target delineation, outcomes and patterns of recurrenceSebastian M Christ, Gilbert Youssef, Shyam K Tanguturi, et al.
Science Translational Medicine|July 19, 2023
Targeting the Siglec-sialic acid axis promotes antitumor immune responses in preclinical models of glioblastomaPhilip Schmassmann, Julien Roux, Alicia Buck, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|August 12, 2025
Quality assurance in the randomized multicentre phase III trial EORTC-1709-BTG/CCTG CE.8 (MIRAGE) for glioblastoma: Results of the radiotherapy delineation benchmark case procedureJonas Willmann, Joost J C Verhoeff, Orit Kaidar-Person, et al.
Pageof 84

Showing results (591-600 of 831) with videos related to

Sort By:
Pageof 84
Genome Biology|January 28, 2015
Chromosome 7 gain and DNA hypermethylation at the HOXA10 locus are associated with expression of a stem cell related HOX-signature in glioblastomaSebastian Kurscheid, Pierre Bady, Davide Sciuscio, et al.
Neuro-Oncology|May 25, 2019
Defining EGFR amplification status for clinical trial inclusionPim J French, Marica Eoli, Juan Manuel Sepulveda, et al.
Brain Pathology (Zurich, Switzerland)|August 31, 2025
cIMPACT-NOW update 11: Proposal on adaptation of diagnostic criteria for IDH- and H3-wildtype diffuse high-grade gliomas and for posterior fossa ependymal tumorsPieter Wesseling, David Capper, Guido Reifenberger, et al.
Nature Medicine|April 1, 2008
Ceramide accumulation mediates inflammation, cell death and infection susceptibility in cystic fibrosisVolker Teichgräber, Martina Ulrich, Nicole Endlich, et al.
Neuro-Oncology|February 11, 2026
The prognostic impact of CDKN2A/B hemizygous deletions in meningiomaFranziska M Ippen, Thomas Hielscher, Areeba Patel, et al.
Neuro-Oncology Practice|March 9, 2026
Ethical considerations in randomization for neurosurgical oncology trials: A scoping reviewNathan A Shlobin, Mira C Hasner, Philipp Karschnia, et al.
Neurology|September 27, 2013
Prognostic or predictive value of MGMT promoter methylation in gliomas depends on IDH1 mutationWolfgang Wick, Christoph Meisner, Bettina Hentschel, et al.
Clinical and Translational Radiation Oncology|December 4, 2023
Re-irradiation of recurrent IDH-wildtype glioblastoma in the bevacizumab and immunotherapy era: Target delineation, outcomes and patterns of recurrenceSebastian M Christ, Gilbert Youssef, Shyam K Tanguturi, et al.
Science Translational Medicine|July 19, 2023
Targeting the Siglec-sialic acid axis promotes antitumor immune responses in preclinical models of glioblastomaPhilip Schmassmann, Julien Roux, Alicia Buck, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|August 12, 2025
Quality assurance in the randomized multicentre phase III trial EORTC-1709-BTG/CCTG CE.8 (MIRAGE) for glioblastoma: Results of the radiotherapy delineation benchmark case procedureJonas Willmann, Joost J C Verhoeff, Orit Kaidar-Person, et al.
Pageof 84